Results 91 to 100 of about 1,454,174 (267)

Functional Gait Recovery after a Combination of Conventional Therapy and Overground Robot-Assisted Gait Training Is Not Associated with Significant Changes in Muscle Activation Pattern: An EMG Preliminary Study on Subjects Subacute Post Stroke [PDF]

, 2021
Francesco Infarinato, Paola Romano, Michela Goffredo, Marco Ottaviani, Daniele Galafate, Annalisa Gison, Simone Petruccelli, Sanaz Pournajaf, Marco Franceschini   +8 more
openalex   +1 more source

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial

, 2022
Yaara Zisman‐Ilani, Kimberly D. Thompson, Lori S. Siegel, Todd A. MacKenzie, Damara Crate, Joshua R. Korzenik, Gil Melmed, Patricia Kozuch, Bruce E. Sands, David T. Rubin, Miguel Regueiro, Raymond K. Cross, Douglas C. Wolf, John S. Hanson, Ronald M. Schwartz, Raluca Vrabie, Michael D. Kreines, Timothy Scherer, Marla C. Dubinsky, Corey A. Siegel   +19 more
openalex   +2 more sources

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study [PDF]

, 2004
Amber Y. Goedkoop, Maarten C. Kraan, Daisy I. Picavet, Menno A. de Rie, Marcel B. M. Teunissen, Jan D. Bos, Paul P. Tak   +6 more
openalex   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC [PDF]

, 2016
Tony Mok, Peter Schmid, Osvaldo Rudy Aren, Óscar Arrieta, Maya Gottfried, Abdul Rahman Jazieh, Rodryg Ramlau, K. Timcheva, Claudio Martín, Stuart McIntosh   +9 more
openalex   +1 more source

151 Combination NK-92MI^CD64 cell therapy approach with therapeutic antibodies to treat metastatic prostate cancer [PDF]

, 2020
Hallie M. Hintz, Bruce Walcheck, Aaron M. LeBeau   +2 more
openalex   +1 more source

Gut microbiota diversity is prognostic in metastatic hormone receptor‐positive breast cancer patients receiving chemotherapy and immunotherapy

Molecular Oncology, EarlyView.
In this exploratory study, we investigated the relationship between the gut microbiota and outcome in patients with metastatic hormone receptor‐positive breast cancer, treated in a randomized clinical trial with chemotherapy alone or chemotherapy in combination with immune checkpoint blockade.
Andreas Ullern, Kristian Holm, Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Corinna Bang, Bjørn Naume, Johannes R. Hov, Jon Amund Kyte   +7 more
wiley   +1 more source

PD‐L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR‐mutant non‐small cell lung cancer cells

Cancer Innovation, 2022
Dantong Sun, Puyuan Xing, Junling Li
doaj   +1 more source